Ideaya Biosciences

This Phase 3 trial tests darovasertib, an oral drug, given before standard local therapy (radiation or surgery) for people with primary uveal melanoma that hasn't spread. The goal is to see if the drug can reduce vision loss and help save the eye from removal. About 520 participa…

This study tests a new drug called IDE574 in people with advanced solid tumors or a specific type of breast cancer (ER+, HER2-). The drug targets two enzymes that help cancer cells grow. The study has two parts: first, testing IDE574 alone in various cancers; second, combining it…

This early-stage trial is testing a new drug called IDE892, alone or combined with another drug (IDE397), in people with advanced solid tumors that lack a gene called MTAP. The study aims to find safe doses and see if the drugs can shrink tumors. About 260 adults with cancers lik…

This study tests a new drug called IDE849 in people with small cell lung cancer and other tumors that have a specific marker (DLL3). The trial has two parts: first, to find the safest dose and check for side effects, and second, to see if the drug shrinks tumors or slows their gr…

This early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …

This study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…